Becton, Dickinson and Co (BDX) has disclosed a new risk, in the Corporate Activity and Growth category.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Becton, Dickinson and Co. faces significant risks in realizing the anticipated benefits from the merger of its Biosciences and Diagnostic Solutions business with Waters. The transaction may not deliver the expected operational, financial, and strategic advantages, potentially leading to increased expenses and diverted resources due to transition service commitments. Additionally, the transaction’s tax-free status for U.S. federal income tax purposes is uncertain, posing a risk of substantial tax liabilities. These factors could negatively impact the company’s business, financial condition, and operational results.
Overall, Wall Street has a Moderate Buy consensus rating on BDX stock based on 2 Buys and 5 Holds.
To learn more about Becton, Dickinson and Co’s risk factors, click here.